|Videos|April 14, 2017
New Parkinson Disease Treatment
Author(s)Bobby Lazzara, MD
Patients with Parkinson disease experiencing “off” episodes on levodopa/carbidopa now have another treatment option.
Advertisement
There is now another option for patients with Parkinson disease. The FDA has approved Xadago (safinamide) tablets as an add-on treatment for patients taking levodopa/carbidopa.
In patients experiencing “off” episodes, safinamide has been shown in two clinical trials to be efficacious in reducing involuntary movement and improving motor function scores.
The most common side effects are falls, nausea, insomnia, and dyskinesia.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- 2025 Women in Neurology Conference: Educating, Mentoring, and Networking
September 15th 2025
- This Week on NeurologyLive® — September 15, 2025
September 15th 2025
- NeurologyLive® Friday 5 — September 12, 2025
September 12th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
2
10 Years of the Women Neurologists Group: A Preview of the 4th Annual Conference
3
NeurologyLive® Brain Games: September 14, 2025
4
2025 Women in Neurology Conference: Educating, Mentoring, and Networking
5